Physician profile
Daniel Reese Shust
NPI 1720461866
$12,983.15
in general payments reported to CMS, 2019-2025
46 companies · $2,984 in 2025
The $2,984 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $765 · 2021: $1,744 · 2022: $1,724 · 2023: $2,435 · 2024: $2,599 · 2025: $2,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,017.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,658.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,568.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,435.70 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $1,315.96 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,144.90 | 2019-2025 | |
| Amgen INC. | $819.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $815.27 | 2021-2025 | |
| Lilly USA, LLC | $516.25 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.37 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $364.29 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $329.20 | 2021-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $208.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $202.16 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $183.66 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $179.74 | 2021-2025 | Nexletol |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.